Is the tiered immunogenicity testing of biologics the adequate approach in preclinical development?

[1]  J. Voorberg,et al.  IgG subclasses of anti‐FVIII antibodies during immune tolerance induction in patients with hemophilia A , 2008, British journal of haematology.

[2]  J. Sailstad,et al.  Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. , 2011, Bioanalysis.

[3]  P. Sørensen.  Neutralizing antibodies against interferon-Beta. , 2008, Therapeutic advances in neurological disorders.

[4]  L. Aarden,et al.  A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. , 2010, Journal of immunological methods.

[5]  Christine J. Bryson,et al.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.

[6]  W. Jiskoot,et al.  Erythropoietin-Associated PRCA: Still an Unsolved Mystery , 2006, Journal of immunotoxicology.

[7]  Lanju Zhang,et al.  Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays. , 2013, Journal of pharmaceutical and biomedical analysis.

[8]  K. Bendtzen,et al.  Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.

[9]  Huub Schellekens,et al.  Immunological mechanism underlying the immune response to recombinant human protein therapeutics. , 2010, Trends in pharmacological sciences.

[10]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[12]  Rafael Ponce,et al.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. , 2009, Regulatory toxicology and pharmacology : RTP.